Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sabrina Kuttruff"'
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Autor:
Harpreet Singh, Christian H. Ottensmeier, Judith R. Kroep, Michael Platten, Andreas von Deimling, Juan Sahuquillo, Eilon Barnea, Cedrik M. Britten, Francisco Martínez-Ricarte, Sebastian Kreiter, Itzhak Rosner, Ghazaleh Tabatabai, Wolfgang Wick, Gleb Slobodin, Hans Skovgaard Poulsen, Sabrina Kuttruff, Sjoerd H. van der Burg, Per thor Straten, Marcos Tatagiba, Dganit Melamed Kadosh, Norbert Hilf, Colette Song, Hans-Georg Rammensee, Frank Winkler, Valérie Dutoit, Ulrik Lassen, Arie Admon, Katrin Frenzel, Pierre-Yves Dietrich, Yael Haimovich, Hideho Okada, Ugur Sahin, Berta Ponsati, Jordi Rodon, John C. Castle, Carlos López-Larrea, Bracha Shraibman
Publikováno v:
Molecular and Cellular Proteomics
Molecular & cellular proteomics : MCP, vol 18, iss 6
Mol Cell Proteomics
Molecular and Cellular Proteomics, Vol. 17, No 11 (2018) pp. 2132-2145
Molecular and Cellular Proteomics, Vol. 18, No 6 (2019) pp. 1255-1268
Molecular and Cellular Proteomics, 17(11), 2132-2145
Molecular & cellular proteomics : MCP, vol 18, iss 6
Mol Cell Proteomics
Molecular and Cellular Proteomics, Vol. 17, No 11 (2018) pp. 2132-2145
Molecular and Cellular Proteomics, Vol. 18, No 6 (2019) pp. 1255-1268
Molecular and Cellular Proteomics, 17(11), 2132-2145
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antig
Autor:
Dominik Maurer, Borje S. Andersson, Jens Fritsche, Arun Satelli, Sabrina Kuttruff-Coqui, Kerstin Guenther, Carsten Reinhardt, Steffen Walter, Mamta Kalra, Ali Mohamed, Apostolia Maria Tsimberidou, Rita Ort, Kerry Sieger, Norbert Hilf, Amir Alpert, Anna Nowak, Becky Norris, Toni Weinschenk, David Vining, Oliver Schoor, Fabian Richter, Patrick Hwu, Zoe Coughlin, Cassian Yee, Regina Mendrzyk, Harpreet Singh, Claudia Wagner
Publikováno v:
Regular and young investigator award abstracts.
Background ACTolog (IMA101) is a personalized multi-target adoptive cell therapy (ACT) approach in which autologous T-cell products are redirected against multiple novel defined peptide-HLA (pHLA) cancer targets identified by the target discovery pla
Autor:
Marij J. P. Welters, Dominik Maurer, Ulrik Lassen, Martin Löwer, Bernhard Rossler, Ugur Sahin, Andreas von Deimling, Toni Weinschenk, Christian H. Ottensmeier, Elisa Rusch, Colette Song, Valérie Dutoit, Jordi Rodon, Norbert Hilf, Hans Skovgaard Poulsen, Nina Pawlowski, Francisco Martínez-Ricarte, Judith R. Kroep, Juan Sahuquillo, Claudia Wagner, Edward W. Green, Sonja Dorner, Cedrik M. Britten, Franziska Hoffgaard, Jens Fritsche, Ghazaleh Tabatabai, Stefan Stevanovic, Harpreet Singh-Jasuja, Marco Skardelly, Sabrina Kuttruff-Coqui, Hans-Georg Rammensee, Katharina Kiesel, Alexander Ulges, Carsten Reinhardt, Michael Platten, Alexandra Kemmer-Brück, Bracha Shraibman, Denis Migliorini, Sebastian Kreiter, Jordi Piro, Oliver Schoor, Valesca Bukur, Katrin Frenzel, Berta Ponsati, David Capper, Jorg Ludwig, Monika Stieglbauer, Regina Mendrzyk, Miriam Meyer, Sjoerd H. van der Burg, Evelyna Derhovanessian, Pierre-Yves Dietrich, Arie Admon, Arbel D. Tadmor, Manja Idorn, Wolfgang Wick, Hideho Okada, Per thor Straten, Sandra Heesch, Lukas Bunse, Christoph Huber, Katy J. McCann, Cécile Gouttefangeas, John C. Castle
Publikováno v:
Nature, 565(7738), 240
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b11cf9d2f3e8456103640b3a57a625
https://hdl.handle.net/1887/119498
https://hdl.handle.net/1887/119498
Autor:
Christian H. Ottensmeier, Juan Sahuquillo, Cedrik M. Britten, Eilon Barnea, Yael Haimovich, Judith R. Kroep, Hans-Georg Rammensee, Hideho Okada, Per thor Straten, Andreas von Deimling, Katrin Frenzel, Itzhak Rosner, Ghazaleh Tabatabai, Dganit Melamed Kadosh, Wolfgang Wick, Sabrina Kuttruff, Harpreet Singh, Sjoerd H. van der Burg, Pierre-Yves Dietrich, Gleb Slobodin, Jordi Rodon, Norbert Hilf, Arie Admon, Sebastian Kreiter, Francisco Martínez-Ricarte, Frank Winkler, Carlos López-Larrea, Colette Song, Valérie Dutoit, Michael Platten, Berta Ponsati, John C. Castle, Ulrik Lassen, Hans Skovgaard Poulsen, Bracha Shraibman, Ugur Sahin, Marcos Tatagiba
Publikováno v:
Molecular & Cellular Proteomics. 18:1270
Autor:
Kerry Sieger, Cassian Yee, Apostolia-Marie Tsimberidou, Steffen Walter, Arun Satelli, Patrick Hwu, Norbert Hilf, Ali Mohamed, Dominik Maurer, Oliver Schoor, Yannick Bulliard, Borje S. Andersson, Sabrina Kuttruff, Carsten Reinhardt, Jens Fritsche, Toni Weinschenk, Geoffrey Stephens, Hong Ma, Chad Stewart, Harpreet Singh
Publikováno v:
Cancer Research. 78:CT127-CT127
Introduction: Adoptive cellular therapy (ACT), which includes the administration of autologous or allogenic anti-tumor T lymphocytes after ex vivo manipulation and expansion, has demonstrated substantial clinical benefit in some hematological cancer
Autor:
Ali Mohamed, Yannick Bulliard, Melinda Mata, Mo Dao, Leonie Alten, Aleksandra Nowicka, Sabrina Kuttruff, Toni Weinschenk, Steffen Walter, Sarah Missel
Publikováno v:
Cancer Research. 78:3588-3588
Adoptive cellular therapy (ACT) has dramatically changed the landscape of cancer immunotherapy; however, the complex manufacture of individualized products from late-stage, heavily pre-treated cancer patients, together with high cost-of-goods, encour
Autor:
Ghazaleh Tabatabai, Stefan Stevanovic, Andreas von Deimling, Wolfgang Wick, Ugur Sahin, Katrin Frenzel, Berta Ponsati, Sabrina Kuttruff, Christian H. Ottensmeier, Sjoerd H. van der Burg, Judith R. Kroep, Cécile Gouttefangeas, Hans Skovgaard Poulsen, Hideho Okada, Pierre-Yves Dietrich, Hans-Georg Rammensee, Francisco Martínez-Ricarte, Harpreet Singh, Arie Admon, Norbert Hilf
Publikováno v:
Journal of Clinical Oncology. 36:2000-2000
2000Background: The need for treatment personalization is obvious as every cancer is molecularly unique. In addition glioblastoma (GB) are immunologically regarded as resistant, “cold” tumor with f...
Autor:
Jessica Spreu, Kevin M. Dennehy, Sabrina Kuttruff, Alexander Steinle, Veronika Stejfova, Birgit Schittek
Publikováno v:
Proceedings of the National Academy of Sciences. 107:5100-5105
Many well-known immune-related C-type lectin-like receptors (CTLRs) such as NKG2D, CD69, and the Ly49 receptors are encoded in the natural killer gene complex (NKC). Recently, we characterized the orphan NKC geneCLEC2Aencoding for KACL, a further mem
Autor:
Oliver Schoor, Jens Fritsche, Joseph F. Costello, Toni Weinschenk, Norbert Hilf, Gary Kohanbash, Josie Hayes, Payal Watchmaker, Sabrina Kuttruff-Coqui, Hideho Okada, Samuel J. Shelton, Colette Song, Diego Carrera, Michael C. Oldham, Soeren Mueller, Harpreet Singh
Publikováno v:
Neuro-Oncology. 19:vi124-vi124
Diffuse infiltrating low-grade gliomas (WHO grade II or III) are slow-growing primary brain tumors, but are considered malignant due to their invasive growth with a high risk of recurrence and progression to higher-grade tumors. While novel immunothe